EUROPEAN STANDARD CLINICAL PRACTICE RECOMMENDATIONS FOR CHILDREN AND ADOLESCENTS WITH PRIMARY AND RELAPSED OSTEOSARCOMA - version 1 - 2023-04-26

Sep 30, 2026

Uploaded by gewufjwa

European standard-of-care guidance for pediatric osteosarcoma covering primary localized, metastatic, and relapsed disease, with recommendations spanning diagnostics, treatment, and supportive care. The document provides state-of-the-art work-up and management suggestions, including technical guidance on imaging and pathology plus directions for further biological examinations. In the absence of current phase III trials, it aims to serve as a consensus comparator for future studies, assuming essential facilities, medicines, and expertise are available.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages69

Reading Time2 h 54 min

AccessFree to download

Introduction

Methodology

Background

EUROPEAN STANDARD CLINICAL PRACTICE RECOMMENDATIONS FOR CHILDREN AND ADOLESCENTS WITH PRIMARY AND RELAPSED OSTEOSARCOMA INTRODUCTORY PAGES • EUROPEAN STANDARD CLINICAL PRACTICE RECOMMENDATIONS FOR CHILDREN AND ADOLESCENTS WITH PRIMARY AND RELAPSED OSTEOSARCOMA • European standard-of-care guidelines for osteosarcoma • version 1 2023-04-26 This document has been developed by: Dr. Roelof van Ewijk Clinical research fellow in pediatric oncology Princess Máxima Center for pediatric oncology Utrecht, the Netherlands Dr. Nikolas Herold Associate professor, fellow in pediatric oncology Astrid Lindgren's Children Hospital Karolinska University Hospital Stockholm, Sweden Supervised by Professor Dr. Leo Kager St. Anna Children’s Hospital & St. Anna Children’s Cancer Research Institute Department of Pediatrics, Medical University Vienna Vienna, Austria Professor Dr. Stefan S. Bielack Klinikum Stuttgart-Olgahospital Stuttgart, Germany Planned review date 2028-04-26 This document contains guidance for the treatment of primary localized as well as metastatic and relapsedosteosarcoma, including diagnostics, treatment and supportive care. This guidance document assumes the availability of essential facilities, supportive care, medicines and expertise to provide care for the intensive and complex treatments. This document provides state-of-the-art work-up and management suggestions, including technical guidance on imaging, pathology, and suggestions for further biological examinations. In the absence of current ongoing phase III trials, it aims to provide a consensus document which might be considered standard-of-care and act as a comparator for future phase III trials in childhood and adolescent osteosarcoma. The document has been developed in collaboration with (alphabetical) : | Fredrik Baecklund | Pediatric Oncology, Astrid Lindgren's Children Hospital, Karolinska University Hospital, Stockholm, Sweden & Childhood Cancer Research Unit, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden | | --- | --- | | Daniel Baumhoer | Bone Tumor Reference Center at the Institute of Medical Genetics and Pathology, University Hospital and University of Basel, Switzerland | | Kjetil Boye | Department of Oncology, Oslo University Hospital, Norway | | Nathalie Gaspar | Department of Oncology for Child and Adolescents, Gustave Roussy Cancer Center, Paris-Saclay University, Villejuif, France | | Semi B. Harrabi | Heidelberg Ion Beam Therapy Center (HIT), Department of Radiation Oncology, University Hospital Heidelberg, Germany | | Lianne M. Haveman | Pediatric Oncology, Princess Máxima Center for pediatric oncology, Utrecht, the Netherlands | | Stefanie Hecker-Nolting | Pediatric Oncology, Klinikum Stuttgart-Olgahospital, Stuttgart, Germany | | Laura Hiemcke-Jiwa | Department of Pathology, Princess Máxima Center for pediatric oncology, Utrecht, the Netherlands | | Valentine Martin | Department of Radiation Oncology, Gustave Roussy Cancer Center, Villejuif, France | | Cristina Mata Fernández | Hospital Universitario Materno Infantil Gregorio Marañón. Pediatric and Adolescent Oncohematology Unit, Madrid, Spain | | Emanuela Palmerini | Department of Oncology, Bone and Soft Tissue Sarcomas and Innovative Therapies, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy | | Michiel A.J. van de Sande | Department of Orthopedic Surgery, Princess Máxima Center for pediatric oncology, Utrecht, the Netherlands
Department of Orthopedic Surgery, Leiden University Medical Center, Leiden, the Netherlands | | Sandra J. Strauss | Department of Oncology, University College London Hospitals NHS Foundation Trust (UCLH), London, UK | DISCLAIMER: These ESCP guidance documents were produced by the relevant tumor group or specialist committee as recommendations on current best practice. The ESCP guidance documents are not clinical trial protocols. The interpretation and responsibility of the use of ESC

FAQs

What patient populations does this ESCP guidance cover for osteosarcoma?

The guidance covers treatment of primary localized osteosarcoma as well as metastatic and relapsed osteosarcoma in children and adolescents.

What kinds of recommendations are included in the document?

It includes state-of-the-art work-up and management suggestions, spanning diagnostics, treatment, and supportive care, with technical guidance on imaging and pathology.

How should clinicians use these recommendations according to the disclaimer?

The guidance is not a clinical trial protocol; responsibility for interpretation and treatment decisions lies with the user, including checking doses and other relevant medical information.

Sep 30, 2026

Uploaded by gewufjwa